SEARCH

SEARCH BY CITATION

References

  • Acquas E, Tanda G, Di Chiara G (2002). Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology 27: 182193.
  • Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1S254.
  • Begg DP, Hallam KT, Norman TR (2005). Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. Behav Brain Res 161: 286290.
  • Bian H, Zhang J, Wu P, Varty LA, Jia Y, Mayhood T et al. (2004). Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol 68: 22292236.
  • Bianco P, Costantini M, Dearden LC, Bonucci E (1988). Alkaline phosphatase positive precursors of adipocytes in the human bone marrow. Br J Haemotol 68: 401403.
  • Brunnenberg M, Lindenblatt H, Gouzoulis-Mayfrank E, Kovar KA (1998). Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl 719: 7985.
  • Camarasa J, Pubill D, Escubedo E (2006). Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res 1111: 7282.
  • Carrillo JA, Benitez J (2000). Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 39: 127153.
  • Cauli O, Morelli M (2005). Caffeine and the dopaminergic system. Behav Pharmacol 16: 6377.
  • Centurión D, Mehotra S, Sanchez-Lopez A, Gupta S, MaassenVanDenBrink A, Villalon CM (2006). Potential vascular alpha1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat. Eur J Pharmacol 535: 234242.
  • Cryan JF, Kelliher P, Kelly JP, Leonard BE (1999). Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: modification by the selective 5-HT(1A) receptor antagonist WAY 100635. J Psychopharmacol 13: 278283.
  • Cryan JF, Harkin A, Naughton M, Kelly JP, Leonard BE (2000). Characterization of d-fenfluramine-induced hypothermia: evidence for multiple sites of action. Eur J Pharmacol 390: 275285.
  • Dafters RI, Biello SM (2003). The effect of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) on serotonergic regulation of the mammalian circadian clock mechanism in rats: the role of dopamine and hyperthermia. Neurosci Lett 350: 117121.
  • De la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M et al. (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137144.
  • Denborough MA, Hopkinson KC (1997). Dantrolene and ‘ecstasy’. Med J Aust 166: 165166.
  • Derlet RW, Tseng JC, Albertson TE (1992). Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am J Emerg Med 10: 211216.
  • Di Matteo V, Di Giovanni G, Pierucci M, Esposito E (2008). Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 172: 744.
  • Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM et al. (2008). Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci 28: 29332940.
  • Dulloo AG, Seydoux J, Girardier L (1991). Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. Int J Obes 15: 317326.
  • Dulloo AG, Seydoux J, Girardier L (1992). Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism 41: 12331241.
  • Dulloo AG, Seydoux J, Girardier L (1994). Paraxanthine (metabolite of caffeine) mimics caffeine's interaction with sympathetic control of thermogenesis. Am J Physiol 267: E801E804.
  • El-Mallakh RS, Abraham HD (2007). MDMA (Ecstasy). Ann Clin Psychiatry 19: 4552.
  • Farré M, De la Torre R, Mathúna BO, Roset PN, Peiró AM, Torrens M et al. (2004). Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173: 364375.
  • Ferré S (2008). An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem 105: 10671079.
  • Ferre S, Ciruela F, Borycz J, Solinas M, Quarta D, Antoniou K et al. (2008). Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 13: 23912399.
  • Fiege M, Wappler F, Weisshorn R, Ulrich Gerbershagen M, Steinfath M, Schulte Am Esch J (2002). Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations. Anaesthesiology 97: 345350.
  • Fisone G, Borgkvist A, Usiello A (2004). Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61: 857872.
  • Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83133.
  • Fuxe K, Ferré S, Zoli M, Agnati LF (1998). Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res Brain Res Rev 26: 258273.
  • Glaser PE, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA (2005). Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. Psychopharmacology (Berl) 178: 250258.
  • Goodwin GM, Green AR (1985). A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) 178: 250258.
  • Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev 55: 463508.
  • Green AR, O'Shea E, Saadat KS, Elliott JM, Colado MI (2005). Studies on the effect of MDMA (‘ecstasy’) on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol 146: 306312.
  • Gudelsky GA, Yamamoto BK (2008). Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90: 198207.
  • Harkin A, Kelly JP, Frawley J, O'Donnell JM, Leonard BE (2000). Test conditions influence the response to a drug challenge in rodents. Pharmacol Biochem Behav 65: 389398.
  • Harkin A, Connor TJ, Mulrooney J, Kelly JP, Leonard BE (2001). Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sci 68: 13671382.
  • Harkin A, Connor TJ, Walsh M, St John N, Kelly JP (2003). Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44: 616623.
  • Hasegawa H, Meeusen R, Sarre S, Diltoer M, Piacentini MF, Michotte Y (2005). Acute dopamine/norepinephrine reuptake inhibition increases brain and core temperature in rats. J Appl Physiol 99: 13971401.
  • Hegadoren KM, Baker GB, Bourin M (1999). 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23: 539553.
  • Henry JA, Jeffreys KJ, Dawling S (1992). Toxicity and deaths from 3,4 methylenedioxymethamphetmaine, (‘Ecstasy’). Lancet 340: 384387.
  • Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB (1996). Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 17: 108113.
  • Jaehne EJ, Salem A, Irvine RJ (2005). Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation. Pharmacolgy Biochem Behavior 81: 485496.
  • Kot M, Daniel WA (2008). Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: the pathway and concentration dependence. Biochem Pharmacol 75: 15381549.
  • Kruuse C, Jacobsen TB, Thomsen LL, Hasselbalch SG, Frandsen EK, Dige-Petersen H et al. (2000). Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects. Eur J Neuro 7: 629638.
  • Linnet K, Koed K, Wiborg O, Gregersen N (1995). Serotonin depletion decreases serotonin transporter mRNA levels in rat brain. Brain Res 697: 251253.
  • Lugnier C (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366398.
  • McCall RB, Schuette MR (1984). Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin. J Pharmacol Exp Ther 228: 704710.
  • McNamara R, Kerans A, O'Neill B, Harkin A (2006). Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (‘Ecstasy’) and MDA (‘Love’). Neuropharmacology 50: 6980.
  • McNamara R, Maginn M, Harkin A (2007). Caffeine induces a profound and persistent tachycardia in response to MDMA (‘Ecstasy’) administration. Eur J Pharmacol 555: 194198.
  • Marston HM, Finlayson K, Maemoto T, Olverman HJ, Akahane A, Sharkey J et al. (1998). Pharmacological characterisation of a simple behavioural response mediated selectively by central adenosine A1 receptors using in vivo and in vitro techniques. J Pharmacol Exp Ther 285: 10231030.
  • Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT (2000). Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’). Toxicology Lett 112-113: 133142.
  • Mazzola-Pomietto P, Aulakh CS, Wozniak KM, Hill JL, Murphy DL (1995). Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology (Berl) 117: 193199.
  • Mechan AO, Esteban B, O'Shea E, Elliott JM, Colada MI, Green AR (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats. Br J Pharmacol 135: 170180.
  • Meskini N, Némoz G, Okyayuz-Baklouti I, Lagarde M, Prigent AF (1994). Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem Pharmacol 47: 781788.
  • Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998). Dopamine receptors: from structure to function. Physiol Rev 78: 189225.
  • Müller T, Engels P, Fozard JR (1996). Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci 17: 294298.
  • Nash JF Jr, Meltzer HY, Gudelsky GA (1988). Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245: 873879.
  • Nehlig A (1999). Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci Biobehav Rev 23: 563576.
  • Nehlig A, Daval JL, Debry G (1992). Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 17: 139170.
  • Okada M, Mizuno K, Kaneko S (1996). Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 212: 5356.
  • Okada M, Kiryu K, Kawata Y, Mizuno K, Wada K, Tasaki H et al. (1997). Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur J Pharmacol 321: 181188.
  • Okada M, Kawata Y, Murakami T, Wada K, Mizuno K, Kondo T et al. (1999). Differential effects of adenosine receptor subtypes on release and reuptake of hippocampal serotonin. Eur J Neurosci 11: 19.
  • Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB (1999). Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmiedebergs Arch Pharmacol 359: 710.
  • Orallo F, Tristan H, Garcia-Ferreiro T, De Francisco S, Masaguer C, Raviña E et al. (2000). Study of the in vivo and in vitro cardiovascular effects of four new analogues of ketanserin: implication of 5-HT2A and alpha1 adrenergic antagonism in their hypotensive effect. Bio Pharm Bul 23: 558565.
  • Penner R, Neher E (1989). The importance of calcium for secretion in excitable and non-excitable cells. Arzneimittelforschung 39: 174177.
  • Puerta E, Hervias I, Goñi-Allo B, Lasheras B, Jordan J, Aguirre N (2009). Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. J Neurochem 108: 755766.
  • Quarta D, Borycz J, Solinas M, Patkar K, Hockemeyer J, Ciruela F et al. (2004). Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem 91: 873880.
  • Ramos AJ, Tagliaferro P, López-Costa JJ, López EM, Pecci Saavedra J, Brusco A (2002). Neuronal and inducible nitric oxide synthase immunoreactivity following serotonin depletion. Brain Res 958: 112121.
  • Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990). Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529: 8590.
  • Shankaran M, Gudelsky GA (1999). A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl) 147: 6672.
  • Solinas M, Ferré S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR (2002). Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 22: 63216324.
  • Sprague JE, Banks ML, Cook VJ, Mills EM (2003). Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305: 159166.
  • Sprague JE, Brutcher RE, Mills EM, Caden D, Rusyniak DE (2004). Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with α1- plus β3-adrenoreceptor antagonists. Br J Pharmacology 142: 667670.
  • Xu L, Tripathy A, Pasek DA, Meissner G (1998). Potential for pharmacology of ryanodine receptor/calcium release channels. Ann N Y Acad Sci 853: 130148.
  • Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA (2002). Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J Neurochem 80: 960969.